Tuesday, de-extinction company Colossal Biosciences closed a mammoth, $150 million Series B financing round and announced plans to resurrect the iconic Dodo – extinct since the 17th century.
https://www.pharmalive.com/wp-content/uploads/2023/01/BioSpaceColossal1-31-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-01-31 11:30:352023-01-31 12:01:48Colossal closes $150M Series B with eye on the iconic dodo